Docality.com Logo
 
Dr. U  Khin  Md image

Dr. U Khin Md

37924 Medical Arts Ct
Zephyrhills FL 33541
813 791-1900
Medical School: Other - 1983
Accepts Medicare: Yes
Participates In eRX: Yes
Participates In PQRS: Yes
Participates In EHR: Yes
License #: ME75158
NPI: 1093704116
Taxonomy Codes:
207R00000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. U Khin is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:G0438 Description:PPPS, initial visit Average Price:$352.00 Average Price Allowed
By Medicare:
$164.49
HCPCS Code:99305 Description:Nursing facility care init Average Price:$255.00 Average Price Allowed
By Medicare:
$128.15
HCPCS Code:99304 Description:Nursing facility care init Average Price:$181.00 Average Price Allowed
By Medicare:
$90.64
HCPCS Code:99309 Description:Nursing fac care subseq Average Price:$173.00 Average Price Allowed
By Medicare:
$86.43
HCPCS Code:99308 Description:Nursing fac care subseq Average Price:$132.00 Average Price Allowed
By Medicare:
$65.91
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$137.85 Average Price Allowed
By Medicare:
$128.82
HCPCS Code:99215 Description:Office/outpatient visit est Average Price:$115.41 Average Price Allowed
By Medicare:
$107.78
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$78.73 Average Price Allowed
By Medicare:
$76.66
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$51.93 Average Price Allowed
By Medicare:
$50.05
HCPCS Code:69210 Description:Remove impacted ear wax Average Price:$34.00 Average Price Allowed
By Medicare:
$33.35

HCPCS Code Definitions

69210
Removal impacted cerumen requiring instrumentation, unilateral
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99215
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family.
99304
Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components: A detailed or comprehensive history; A detailed or comprehensive examination; and Medical decision making that is straightforward or of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of low severity. Typically, 25 minutes are spent at the bedside and on the patient's facility floor or unit.
99305
Initial nursing facility care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission are of moderate severity. Typically, 35 minutes are spent at the bedside and on the patient's facility floor or unit.
99308
Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 15 minutes are spent at the bedside and on the patient's facility floor or unit.
99309
Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient has developed a significant complication or a significant new problem. Typically, 25 minutes are spent at the bedside and on the patient's facility floor or unit.
G0438
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1649252370
Cardiovascular Disease (Cardiology)
6,311
1346448727
Pulmonary Disease
3,214
1457460479
Medical Oncology
3,122
1124096060
Urology
2,844
1063525285
Cardiovascular Disease (Cardiology)
2,796
1124080668
Diagnostic Radiology
2,712
1508979311
Cardiovascular Disease (Cardiology)
2,431
1881705143
Pulmonary Disease
1,628
1588687248
Internal Medicine
1,548
1043218118
Ophthalmology
1,200
*These referrals represent the top 10 that Dr. Khin has made to other doctors

Publications

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. - Clinical cancer research : an official journal of the American Association for Cancer Research
Chronic myelogenous leukemia (CML) results from the breakpoint cluster region-Abl fusion gene product, a tyrosine kinase involved in cell division and apoptosis. Imatinib, an orally administered inhibitor of the breakpoint cluster region-Abl tyrosine kinase, is capable of blocking proliferation and inducing apoptosis in CML cell lines. In this report, we describe the preclinical profile of imatinib and the data submitted in the New Drug Application that led to its marketing approval.Chemistry manufacturing and controls, animal toxicology, and biopharmaceutical data are described. Results of Phase I and Phase II clinical studies in patients with CML in blast crisis (CML-BC), in accelerated phase (CML-AP), and in chronic phase disease-resistant or intolerant to IFN-alpha (CML-CP) are summarized. The basis for marketing approval and postmarketing commitments by the pharmaceutical company are discussed.Toxicology studies in the rat, dog, and monkey show the hematological, renal, and hepatobiliary toxicity of imatinib. Pharmacokinetic studies in patients with CML demonstrate 98% imatinib bioavailability. The elimination half-lives of the parent drug and the major active metabolite, CGP74588, from plasma are approximately 18 and 40 h, respectively. Approximately 81% of the drug is eliminated in 7 days, 68% in the feces and 13% in the urine. Cytochrome P-450 3A4 is the main enzyme responsible for imatinib metabolism. Phase I and II clinical studies were conducted. The Phase I study, in 83 CML patients, evaluated oral imatinib doses from 25 to 1000 mg/day. Dose-limiting toxicity was not observed. The three Phase II studies, in CML-CP, CML-AP, and CML-BC, enrolled 1027 patients. CML-CP patients received 400 mg/day imatinib, whereas CML-AP and CML-BC patients generally received 600 mg/day imatinib. Primary study endpoints were cytogenetic response rate (CML-CP) and hematological response rate (CML-AP and CML-BC). The cytogenetic response rate for CML-CP patients was 49%. The hematological response rate of CML-AP and CML-BC patients was 63 and 26%, respectively. The most common imatinib adverse events were nausea, vomiting, myalgia, edema, and diarrhea. Elevated liver enzymes and/or bilirubin were reported in 27 patients (2.6%).On May 10, 2001, imatinib mesylate (Gleevec, formerly known as STI-571 and Glivec), manufactured and distributed by Novartis Pharmaceuticals, East Hanover, NJ, was approved by the United States Food and Drug Administration for the treatment of CML in three clinical settings: CML-BC, CML-AP, and CML-CP. This report summarizes the Food and Drug Administration's review of the New Drug Application.
Myelography wiht perfluoroctylbromide. Comparison with Pantopaque. - Investigative radiology
The efficacy and toxicity of perfluoroctylbromide in myelography were studied in dogs. Perfluoroctylbromide moves freely in intrathecal space and provides satisfactory radiopacity for diagnosis of subarachnoid structures. The outstanding feature of this substance is its low toxicity. The dog tolerates 0.5-1.0 ml/kg intrathecally without toxic manifestation. Histological studies and CSF analyses show that it is much less irriating than Pantopaque. Because of the long retention of the perfluorocarbon removal may be necessary. Perfluoroctylbromide shows promise as a diagnostic contrast medium, particularly in cases where the currently available contrast media are not suitable.

Map & Directions

37924 Medical Arts Ct Zephyrhills, FL 33541
View Directions In Google Maps

Nearby Doctors

7631 Gall Blvd
Zephyrhills, FL 33541
208 516-6196
37840 Medical Arts Ct
Zephyrhills, FL 33541
813 885-5569
37924 Medical Arts Ct
Zephyrhills, FL 33541
813 806-6687
37922 Medical Arts Ct
Zephyrhills, FL 33541
352 182-2000
37908 Daughtery Rd Suite A
Zephyrhills, FL 33541
813 596-6007
37840 Medical Arts Ct
Zephyrhills, FL 33541
813 885-5569
7050 Gall Blvd
Zephyrhills, FL 33541
813 836-6111
4924 S. Allen Road
Zephyrhills, FL 33541
813 798-8591
37908 Daughtery Rd Suite B
Zephyrhills, FL 33541
813 024-4944